Taisho Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Taisho Pharmaceutical Co., Ltd.
Hikma is looking for a new CEO after announcing that chief executive Siggi Olafsson will be leaving the company “to pursue other opportunities” on 24 June. In the meantime, executive chairman and former CEO Said Darwazah will take on his leadership responsibilities.
A few cases of COVID-19 relapse have Twitter abuzz about the need for data on Paxlovid’s effectiveness, particularly against the Omicron variant and in vaccinated individuals. Despite regulatory approval in India, the drug has not yet been included in treatment guidelines and a debate on recommended dosage now complicates matters
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
Just days after forecasting healthy generics sales growth for 2022, Hikma has significantly reduced its expectations for the year on news of a delay to its US launch of an authorized generic of Xyrem (sodium oxybate).
- Topical Delivery
- Drug Delivery
- Other Names / Subsidiaries
- Hoepharma Holdings Sdn. Bhd.
- Taisho Toyama Pharmaceutical Co., Ltd.
- TOKUHON Corporation
- UPSA SAS